Table 2.
Characteristics of CSRV by screening period in patients with positive PCR.
| P1 | P2 | P3 | P-value | |
|---|---|---|---|---|
| PCR+ episodes, n (%) | 115 (38.3) | 145 (48.3) | 40 (13.3) | P < 0.001 |
| Median days from allo-HSCT to CSRV (range) | 260 (−8 to 4766) | 275 (−7 to 3993) | 473 (−4 to 5422) | P = 0.015 |
| Flu vaccination, n (%) | 24 (20.9) | 66 (45.5) | 21 (52.5) | P < 0.001 |
| IgG mg/dL, median (range) | 577 (109–1350) | 662 (0–14100) | 702 (220–1716) | ns |
| Immunoglobulin support, n (%) | 15 (13) | 19 (13.1) | 7 (17.5) | ns |
| HLA mismatched donor/recipient, n (%) | 45 (39.1) | 51 (35.2) | 12 (30) | ns |
| Age ≥ 40, n (%) | 71 (61.7) | 115 (79.3) | 31 (77.5) | P = 0.005 |
| MAC regimen, n (%) | 72 (62.6) | 70 (48.3) | 23 (57.5) | ns |
| ALC < 0.5 × 10e9/mL, n (%) | 27 (23.5) | 28 (19.3) | 6 (15) | ns |
| ANC < 0.5 × 10e9/mL, n (%) | 5 (4.3) | 9 (6.2) | 0 (0) | ns |
| Active GvHD, n (%) | 57 (49.6) | 65 (44.8) | 15 (37.5) | ns |
| Under IST, n (%) | 75 (65.2) | 95 (65.5) | 22 (55) | ns |
| Corticosteroids, n (%) | 30 (26.1) | 32 (22.1) | 6 (15) | ns |
| ISI (Low-moderate-high risk), n (%) | 48–57–10 (41.7–49.6–8.7) | 51–84–8 (35.2–57.9–5.5) | 13–23–0 (35–62.5–0) | ns |
| Antibiotic therapy, n (%) | 82 (71.4) | 105 (72.4) | 30 (75) | ns |
| Fever (>37.8 °C), n (%) | 47 (40.9) | 62 (42.8) | 20 (50) | ns |
| URTD, n (%) | 111 (96.5) | 142 (97.9) | 33 (82.5) | P < 0.001 |
| LRTD, n (%) | 55 (47.8) | 39 (26.9) | 15 (37.5) | P = 0.002 |
| CSRV co-infection, n (%) | 25 (21.7) | 24 (16.6) | 2 (5) | P = 0.051 |
| Hospitalization, n (%) | 39 (34) | 34 (23.4) | 10 (25) | |
| Day-90 all-cause mortality, n (%) | 2 (1.8) | 2 (1.4) | 5 (12.5) | P = 0.001 |
| Median follow-up after CSRV, days (range) | 720 (14–950) | 426 (7–580) | 138 (5–224) | P < 0.001 |
CSRV common seasonal respiratory virus, +PCR positive polymerase chain reaction, allo-HSCT allogenic hematopoietic stem cell transplant, IgG immunoglobulin G, HLA major histocompatibility complex/human leukocyte antigen, MAC myeloablative, GvHD graft versus host disease, IST immunosuppressive therapy, ISI immunodeficiency scoring index, URTD upper respiratory tract disease, LRTD low respiratory tract disease, Max fever maximum temperature, RCP reactive c protein, ALC absolute lymphocytes count, ANC absolute neutrophil count, P1 period 1, P2 period 2, P3 period 3, ns not significant.